Key Highlights

  • Johnson & Johnson's $1.34 quarterly Dividend trades ex-date August 25, 2026, payable September 8.
  • The dividend yields approximately 1.98%, following a 3.1% increase that marks the company's 64th consecutive year of dividend growth.
  • Second-quarter 2026 sales reached approximately $25.3 billion, up 6.6% reported, with adjusted EPS of $2.90.
  • The company raised its full-year 2026 outlook to approximately $101.1 billion in sales and adjusted EPS of $11.68 at the midpoint.

Dividend Program and Shareholder Returns

Johnson & Johnson (NYSE:JNJ) raised its quarterly dividend by 3.1%, from $1.30 to $1.34 per share, trading ex-dividend on August 25, 2026, payable September 8 to shareholders of record. The dividend yields approximately 1.98% at current market prices. The increase marked the company's 64th consecutive year of dividend increases, an exceptionally long track record supported by J&J's diversified Operating Cash Flow across its Innovative Medicine and MedTech businesses.

About the Company

Johnson & Johnson is a diversified healthcare company operating through Innovative Medicine, which develops prescription medicines in immunology, oncology, and neuroscience, and MedTech, which supplies surgical, orthopedic, and cardiovascular technologies. The company's scale and Diversification provide some insulation across different healthcare markets, though Patent expirations and litigation remain structural considerations.

Financial Performance Behind the Payout

J&J reported second-quarter 2026 sales of approximately $25.3 billion, up 6.6% reported and 5.6% operationally. Net Earnings were approximately $5.53 billion, with diluted GAAP EPS of $2.27 and adjusted EPS of $2.90, up 4.7% year over year. Innovative Medicine sales increased approximately 7.8%, while MedTech sales increased about 4.5%. For the first six months, sales reached approximately $49.4 billion with operating cash flow of approximately $11.1 billion.

A Diversified Portfolio With Ongoing Legal Considerations

J&J raised its full-year 2026 outlook following the strong quarter, reflecting confidence in both its pharmaceutical and medical-device segments. The company also announced a $1 billion Firefly Bio deal, continuing its business-development strategy. However, J&J's disclosures continue to include a substantial talc-related litigation reserve, which investors should Factor into their assessment of the company's legal liabilities separate from its operational performance. Pipeline productivity and the durability of growth in key medicines remain central to the long-term Investment case.

Outlook

Johnson & Johnson's 64-year dividend-growth streak reflects one of the longest and most reliable records among large-cap companies, supported by diversified cash flow across pharmaceuticals and medical technology. The raised full-year guidance reinforces near-term confidence. The primary considerations for investors are the trajectory of talc-related legal costs, pipeline productivity, and the durability of growth in Innovative Medicine and MedTech as the company navigates patent expirations and competitive pressures.